Advertisement

---

FLEXION THERAPEUTICS, INC.

Flexion's FX006 Demonstrates Superior Pain Relief Compared to Standard-of-Care in Phase 2b Osteoarthritis Trial

[2013-06-26] - - FX006 Provides Pain Relief Signal That is Among the Largest Seen in Osteoarthritis Clinical Trials -
- Optimal Dose for Phase 3 Trial Identified -


Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer

[2013-05-20] -


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers